[HTML][HTML] Loss of beta cell function as fasting glucose increases in the non-diabetic range

IF Godsland, JAR Jeffs, DG Johnston - Diabetologia, 2004 - Springer
IF Godsland, JAR Jeffs, DG Johnston
Diabetologia, 2004Springer
Aims/hypothesis Our aim was to define the level of glycaemia at which pancreatic insulin
secretion, particularly first-phase insulin release, begins to decline. Methods Plasma
glucose and insulin concentrations were measured during an IVGTT in 553 men with non-
diabetic fasting plasma glucose concentrations. In 466 of the men C-peptide was also
estimated. IVGTT insulin secretion in first and late phases was assessed by:(i) the circulating
insulin response;(ii) population parameter deconvolution analysis of plasma C-peptide …
Aims/hypothesis
Our aim was to define the level of glycaemia at which pancreatic insulin secretion, particularly first-phase insulin release, begins to decline.
Methods
Plasma glucose and insulin concentrations were measured during an IVGTT in 553 men with non-diabetic fasting plasma glucose concentrations. In 466 of the men C-peptide was also estimated. IVGTT insulin secretion in first and late phases was assessed by: (i) the circulating insulin response; (ii) population parameter deconvolution analysis of plasma C-peptide concentrations; and (iii) a combined model utilising both insulin and C-peptide concentrations. Measurements of insulin sensitivity and elimination were also derived by modelling analysis.
Results
As fasting plasma glucose (FPG) increased, IVGTT first-phase insulin secretion declined by 73%, 71% and 68% for the three methods respectively. The FPG values at which this decline began, determined by change point regression, were 4.97, 5.16 and 5.42 mmol/l respectively. The sensitivity of late-phase insulin secretion to glucose declined at FPG concentrations above 6.0 mmol/l. Insulin elimination, but not insulin sensitivity, varied with FPG.
Conclusions/interpretation
The range of FPG over which progressive loss of the first-phase response begins may be as low as 5.0 to 5.4 mmol/l, with late-phase insulin responses declining at FPG concentrations above 6.0 mmol/l.
Springer